Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
November 20, 2023 09:13 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage...
Rakovina Therapeutics Inc. Announces Q2 2023 Financial Results and Provides Corporate Update
August 29, 2023 08:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
Rakovina Therapeutics Announces Results from 2023 Annual General Meeting
June 28, 2023 22:55 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update
May 31, 2023 09:05 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing
May 29, 2023 20:57 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) is pleased to announce that it has closed its previously announced...
Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing
May 01, 2023 22:44 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting
April 20, 2023 12:47 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of new data describing the progress of the...
Rakovina Therapeutics to Present at the Emerging Growth Conference on April 19, 2023
April 17, 2023 18:18 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”) is pleased to announce that it has been invited to present at...
Rakovina Therapeutics Inc. Announces Enhanced Liquidity and Investor Awareness Programs
March 30, 2023 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the engagement of Red Cloud Securities (“Red Cloud”) and...
Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies
March 22, 2023 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), is pleased to announce that it is receiving advisory services and up to...